

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568 **E-mail:** bpgoffice@wjgnet.com https://www.wjgnet.com

## PEER-REVIEW REPORT

Name of journal: World Journal of Nephrology

Manuscript NO: 67983

Title: Efficacy and Safety of Recombinant Human Erythropoietin (Hema-Plus®) for

Management of Anemia in Thai Patients on Peritoneal Dialysis

Reviewer's code: 05946247

**Position:** Peer Reviewer

Academic degree: MD

Professional title: Doctor

Reviewer's Country/Territory: Ethiopia

Author's Country/Territory: Thailand

Manuscript submission date: 2021-05-09

Reviewer chosen by: AI Technique

Reviewer accepted review: 2021-05-10 14:15

Reviewer performed review: 2021-05-13 16:19

**Review time:** 3 Days and 2 Hours

Scientific quality	[ ] Grade A: Excellent [Y] Grade B: Very good [ ] Grade C: Good [ ] Grade D: Fair [ ] Grade E: Do not publish
Language quality	<ul> <li>[ ] Grade A: Priority publishing [Y] Grade B: Minor language polishing</li> <li>[ ] Grade C: A great deal of language polishing [ ] Grade D: Rejection</li> </ul>
Conclusion	<ul> <li>[ ] Accept (High priority) [Y] Accept (General priority)</li> <li>[ ] Minor revision [ ] Major revision [ ] Rejection</li> </ul>
Re-review	[Y]Yes []No
Peer-reviewer statements	Peer-Review: [Y] Anonymous [] Onymous Conflicts-of-Interest: [] Yes [Y] No



7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568 **E-mail:** bpgoffice@wjgnet.com https://www.wjgnet.com

## SPECIFIC COMMENTS TO AUTHORS

This interesting, clear, statistically sound and well-written Prospective Study, Efficacy and Safety of Recombinant Human Erythropoietin (Hema-Plus®) for Management of Anemia in Thai Patients on Peritoneal Dialysis. I have some minor observations to increase quality of the manuscript. 1. Typographical errors: Page 9 paragraph 1 line 2 patents instead of patients Page 11 paragraph 1 line 1 and 5, what do you mean by AEs and SAEs? First notations should be written fully Page 12 paragraph 1 line 6 and 7, paragraph 2, line 12 review 2. How did you control your co-founders? 3.Discussion is not enough